Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 14 · below the Ichimoku cloud · RSI 61 · MACD above its signal
| 1.87 | 52-week high | +43.46% |
| 1.46 | R3 (classic) | +12.05% |
| 1.39 | R2 (classic) | +7.18% |
| 1.33 | Previous day high | +2.31% |
| 1.32 | R1 (classic) | +1.67% |
| 1.30 | Previous month high | +0.38% |
| 1.30 | Price now | |
| 1.26 | Pivot | −3.21% |
| 1.20 | Previous day low | −8.08% |
| 1.19 | S1 (classic) | −8.72% |
| 1.12 | S2 (classic) | −13.59% |
| 1.12 | Previous month low | −13.85% |
| 1.11 | Previous week high | −15.00% |
| 1.05 | S3 (classic) | −19.10% |
| 0.9640 | Previous week low | −25.85% |
| 0.6430 | 52-week low | −50.54% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.4M | 0.00% | 1.91M | −4.1% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MXCT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -41.5 | -10.6 | -13.3 | 25.2 | 37.5 | 1.7 | -14.6 | 22.9 | -13.2 | 16.1 | −16.1% | ||
| 2025 | 8.4 | -25.9 | -18.3 | 4.0 | -16.2 | -8.4 | -5.5 | -32.5 | 13.7 | -2.5 | 14.3 | -11.9 | −62.7% |
| 2024 | 8.3 | -9.6 | -8.9 | -13.4 | 23.4 | -12.5 | 22.4 | -10.0 | -10.0 | -8.0 | -0.8 | 17.2 | −11.5% |
| 2023 | 7.0 | -22.3 | 9.0 | 1.0 | -18.4 | 12.5 | -2.6 | -18.1 | -14.8 | -5.1 | 60.5 | -1.1 | −13.9% |
| 2022 | -36.6 | 7.7 | 0.4 | -20.7 | -16.8 | 2.6 | 15.2 | -4.6 | 25.0 | 6.5 | -13.4 | -8.8 | −46.4% |
| 2021 | -9.6 | -20.5 | -7.9 | -11.2 | 2.1 | −40.1% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Douglas Richard HDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Erck Stanley CDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Balthrop Patrick J SrDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Collins CynthiaDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Al-Wakeel Yasir BDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Hemrajani RekhaDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Brooke William W.Director | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Jun 16, 2026 | Johnston John JosephDirector | Stock Award(Grant) at price 0.00 per share. | 30.4K | — |
| Apr 14, 2026 | Ahuja ParmeetChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 187.5K | — |
| Mar 26, 2026 | Masoud MaherChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 300K | — |
| Mar 16, 2026 | Swirsky Douglas JChief Financial Officer | Sale at price 0.82 per share. | 10.1K | $8.27K |
| Aug 12, 2025 | Douglas Richard HDirector | Purchase at price 1.39 per share. | 80K | $111.04K |
| Aug 12, 2025 | Erck Stanley CDirector | Purchase at price 1.37 per share. | 100K | $137.22K |
| Aug 12, 2025 | Swirsky Douglas JChief Financial Officer | Purchase at price 1.29 per share. | 50K | $64.50K |
| Aug 12, 2025 | Brooke William W.Director | Purchase at price 1.29 per share. | 50K | $64.50K |
| Aug 12, 2025 | Masoud MaherChief Executive Officer | Purchase at price 1.37 per share. | 75K | $102.92K |
| Jun 24, 2025 | Hemrajani RekhaDirector | Sale at price 2.09 per share. | 10.7K | $22.38K |
| Jun 17, 2025 | Douglas Richard HDirector | Stock Award(Grant) at price 0.00 per share. | 29.2K | — |
| Jun 17, 2025 | Erck Stanley CDirector | Stock Award(Grant) at price 0.00 per share. | 29.2K | — |
| Jun 17, 2025 | Balthrop Patrick J SrDirector | Stock Award(Grant) at price 0.00 per share. | 29.2K | — |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Buy / hold / sell counts